Wilms Tumor Ppt New — ((link))

Title Slide

Wilms Tumor (Nephroblastoma) An Embryonal Renal Malignancy of Childhood

• Neoadjuvant (Pre-op): Used in Europe (SIOP protocols) to shrink tumor.
• Adjuvant (Post-op): Standard in US (COG protocols).
• Agents: Vincristine, Dactinomycin, Doxorubicin (for higher stages).

Wilms Tumor (Nephroblastoma) is the most common primary renal malignancy in children, accounting for approximately 90% of pediatric kidney cancers. As of 2025–2026, clinical guidelines from the National Comprehensive Cancer Network (NCCN) and the Children's Oncology Group (COG) emphasize a multimodal approach that has pushed the 5-year survival rate for favorable histology cases above 90%. 1. Clinical Presentation & Predisposition wilms tumor ppt new

If you're interested in learning more about Wilms tumor or would like to access the PPT, we recommend visiting the following resources: Title Slide Wilms Tumor (Nephroblastoma) An Embryonal Renal

: Accounts for 5% of all childhood cancers and ~90% of pediatric renal tumors. : Peak incidence occurs between 3 to 4 years : Approximately 1 in 10,000 children globally. Slide 3: Etiology & Genetics Pathogenesis Neoadjuvant (Pre-op): Used in Europe (SIOP protocols) to

1. AREN1922 (COG) – Reducing therapy for stage II favorable with loss of heterozygosity 1p/16q.
2. SIOP UMBRELLA 2016 – Long-term outcome of blastemal type receiving intensified regimen.
3. ITCC-082 (international) – Pembrolizumab + chemotherapy for first relapse.
4. NCT05556698 – WT1 peptide vaccine for high-risk patients (minimal residual disease).